دورية أكاديمية
MicroRNA-214 in Health and Disease.
العنوان: | MicroRNA-214 in Health and Disease. |
---|---|
المؤلفون: | Amin MMJ; Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, UK., Trevelyan CJ; Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, UK., Turner NA; Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, UK. |
المصدر: | Cells [Cells] 2021 Nov 23; Vol. 10 (12). Date of Electronic Publication: 2021 Nov 23. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
مواضيع طبية MeSH: | Cell Proliferation/*genetics , MicroRNAs/*genetics , Neoplasms/*genetics, Apoptosis/genetics ; Cardiotonic Agents/metabolism ; Cell Differentiation/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Neoplasms/pathology |
مستخلص: | MicroRNAs (miRNAs) are endogenously expressed, non-coding RNA molecules that mediate the post-transcriptional repression and degradation of mRNAs by targeting their 3' untranslated region (3'-UTR). Thousands of miRNAs have been identified since their first discovery in 1993, and miR-214 was first reported to promote apoptosis in HeLa cells. Presently, miR-214 is implicated in an extensive range of conditions such as cardiovascular diseases, cancers, bone formation and cell differentiation. MiR-214 has shown pleiotropic roles in contributing to the progression of diseases such as gastric and lung cancers but may also confer cardioprotection against excessive fibrosis and oxidative damage. These contrasting functions are achieved through the diverse cast of miR-214 targets. Through silencing or overexpressing miR-214, the detrimental effects can be attenuated, and the beneficial effects promoted in order to improve health outcomes. Therefore, discovering novel miR-214 targets and understanding how miR-214 is dysregulated in human diseases may eventually lead to miRNA-based therapies. MiR-214 has also shown promise as a diagnostic biomarker in identifying breast cancer and coronary artery disease. This review provides an up-to-date discussion of miR-214 literature by describing relevant roles in health and disease, areas of disagreement, and the future direction of the field. |
References: | Genes Dev. 2007 Mar 15;21(6):644-8. (PMID: 17369397) Int J Mol Med. 2018 Jul;42(1):461-470. (PMID: 29693173) Pharmacol Ther. 2009 Aug;123(2):255-78. (PMID: 19460403) Mol Ther Nucleic Acids. 2020 Oct 15;22:971-980. (PMID: 33251046) Anat Rec (Hoboken). 2016 Oct;299(10):1348-57. (PMID: 27357906) Med Sci Monit. 2020 Feb 14;26:e918932. (PMID: 32057034) RNA Biol. 2015;12(3):343-53. (PMID: 25826666) Mol Cell Biol. 2007 Jun;27(12):4217-27. (PMID: 17438131) Am J Pathol. 1999 Sep;155(3):703-10. (PMID: 10487827) Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162. (PMID: 30423142) Mol Ther. 2018 Aug 1;26(8):2008-2018. (PMID: 29929788) Cancer Res. 2008 Jan 15;68(2):425-33. (PMID: 18199536) Cancer Cell Int. 2013 Jul 08;13(1):68. (PMID: 23834902) Cell Physiol Biochem. 2018;46(2):757-764. (PMID: 29621773) Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5148-5154. (PMID: 28051254) Sci Rep. 2015 Dec 22;5:18351. (PMID: 26692091) EJIFCC. 2019 Jun 24;30(2):114-127. (PMID: 31263388) Cell J. 2015 Fall;17(3):461-70. (PMID: 26464817) Cancer Res. 2004 Sep 1;64(17):5943-7. (PMID: 15342372) Clin Cancer Res. 2010 Mar 1;16(5):1577-86. (PMID: 20179230) Biomed Pharmacother. 2018 Sep;105:545-552. (PMID: 29886375) EMBO Rep. 2011 May;12(5):451-7. (PMID: 21415858) Cell Biochem Funct. 2011 Jul;29(5):378-83. (PMID: 21520152) Fibrogenesis Tissue Repair. 2012 Aug 01;5(1):12. (PMID: 22849305) Circ Res. 2005 Oct 28;97(9):916-21. (PMID: 16179590) J Clin Invest. 2012 Apr;122(4):1222-32. (PMID: 22426211) Oncotarget. 2017 Mar 21;8(12):19866-19878. (PMID: 28186995) Science. 1997 Mar 28;275(5308):1943-7. (PMID: 9072974) Nucleic Acids Res. 2019 Apr 23;47(7):3353-3364. (PMID: 30820533) Cancer Res. 2016 Sep 1;76(17):5151-62. (PMID: 27328731) Nature. 2007 Jul 5;448(7149):83-6. (PMID: 17589500) Mol Med Rep. 2019 May;19(5):4035-4042. (PMID: 30942417) Stem Cells Int. 2017;2017:3028647. (PMID: 29213288) Genome Res. 2009 Jul;19(7):1175-83. (PMID: 19336450) Cell Mol Life Sci. 2014 Feb;71(4):549-74. (PMID: 23649149) Biochem Biophys Res Commun. 2013 Sep 13;439(1):47-53. (PMID: 23962428) Steroids. 2020 Feb;154:108533. (PMID: 31678133) Cancer Cell. 2006 Mar;9(3):189-98. (PMID: 16530703) Int J Sports Med. 2019 Dec;40(14):931-940. (PMID: 31639865) IUBMB Life. 2009 Nov;61(11):1075-82. (PMID: 19859982) J Mol Cell Cardiol. 2000 May;32(5):817-30. (PMID: 10775486) Immunogenetics. 2016 Jan;68(1):43-54. (PMID: 26563334) Cytotherapy. 2020 Aug;22(8):412-423. (PMID: 32561161) Stem Cell Res Ther. 2020 Nov 3;11(1):465. (PMID: 33143723) Circ Res. 2011 Jan 21;108(2):219-34. (PMID: 21252150) Circ Res. 1994 Sep;75(3):443-53. (PMID: 8062418) Haematologica. 2013 Apr;98(4):640-8. (PMID: 23100276) Int J Mol Med. 2016 May;37(5):1421-8. (PMID: 26951965) N Engl J Med. 2010 Jun 24;362(25):2380-8. (PMID: 20573926) Dev Dyn. 2008 Dec;237(12):3738-48. (PMID: 18985749) J Mol Cell Cardiol. 2009 Jul;47(1):5-14. (PMID: 19336275) FASEB J. 2021 Jan;35(1):e21150. (PMID: 33161580) PLoS One. 2012;7(2):e31518. (PMID: 22359598) Biomaterials. 2016 Jan;74:155-66. (PMID: 26454414) Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7469-7474. (PMID: 31539134) Mol Biosyst. 2014 Jul;10(7):1932-9. (PMID: 24802081) Br J Cancer. 2016 Sep 6;115(6):741-51. (PMID: 27537384) Anticancer Agents Med Chem. 2016;16(3):318-34. (PMID: 26234359) Oncotarget. 2016 Nov 29;7(48):78331-78342. (PMID: 27823969) Cancer Res. 2007 Sep 15;67(18):8699-707. (PMID: 17875710) Stem Cell Rev Rep. 2012 Dec;8(4):1129-37. (PMID: 23054963) Dev Biol. 2016 Feb 1;410(1):1-13. (PMID: 26708096) Cell Cycle. 2014;13(22):3519-28. (PMID: 25483088) J Geriatr Cardiol. 2013 Mar;10(1):34-8. (PMID: 23610572) Eur J Pharmacol. 2017 Dec 5;816:138-145. (PMID: 28842125) Carcinogenesis. 2011 Nov;32(11):1607-14. (PMID: 21828058) Biochem Biophys Res Commun. 2012 Nov 30;428(4):525-31. (PMID: 23068095) J Am Soc Nephrol. 2014 Jan;25(1):65-80. (PMID: 24158985) Am J Pathol. 1995 Aug;147(2):325-38. (PMID: 7639329) J Cell Physiol. 2018 Jan;234(1):231-245. (PMID: 30076721) Cell. 1993 Dec 3;75(5):843-54. (PMID: 8252621) Connect Tissue Res. 2018 Mar;59(2):99-107. (PMID: 28324674) Mol Cell. 2009 Oct 9;36(1):61-74. (PMID: 19818710) Nucleic Acids Res. 2009 Jan;37(1):123-8. (PMID: 19029138) Mol Ther. 2018 Mar 7;26(3):774-783. (PMID: 29456019) Eur Rev Med Pharmacol Sci. 2017 Nov;21(21):4777-4783. (PMID: 29164587) FASEB J. 2018 Sep;32(9):4941-4954. (PMID: 29601781) Clin Sci (Lond). 2019 Sep 10;133(17):1845-1856. (PMID: 31434695) Hum Gene Ther. 2006 Mar;17(3):280-90. (PMID: 16544977) Mech Ageing Dev. 2008 Sep;129(9):534-41. (PMID: 18561983) Lancet Oncol. 2011 Aug;12(8):735-42. (PMID: 21783417) PLoS One. 2014 Jan 21;9(1):e86149. (PMID: 24465927) Int J Oncol. 2018 Apr;52(4):1071-1080. (PMID: 29532857) Cell Res. 2014 Oct;24(10):1164-80. (PMID: 25223704) J Mol Cell Cardiol. 2009 Jun;46(6):821-31. (PMID: 19265700) Cardiovasc Res. 2012 Mar 15;93(4):545-54. (PMID: 22072632) Cell Death Dis. 2013 Sep 05;4:e787. (PMID: 24008731) Oncol Rep. 2016 Jun;35(6):3178-84. (PMID: 27109339) Biochem Biophys Res Commun. 2010 Apr 16;394(4):921-7. (PMID: 20230785) Front Endocrinol (Lausanne). 2018 Aug 03;9:402. (PMID: 30123182) Cell Physiol Biochem. 2016;38(2):809-20. (PMID: 26872365) Sci Rep. 2017 Jan 10;7:40487. (PMID: 28071724) Physiol Rev. 2016 Oct;96(4):1297-325. (PMID: 27535639) Cancer Res. 2010 Aug 1;70(15):6359-67. (PMID: 20631072) PLoS One. 2008 Jul 02;3(7):e2557. (PMID: 18596939) Physiol Rev. 2008 Apr;88(2):581-609. (PMID: 18391174) Lancet Oncol. 2010 Feb;11(2):136-46. (PMID: 20022810) Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616) PLoS One. 2008 Sep 16;3(9):e3225. (PMID: 18795099) Acta Biochim Biophys Sin (Shanghai). 2019 Aug 5;51(8):791-798. (PMID: 31294443) EMBO J. 2011 May 18;30(10):1990-2007. (PMID: 21468029) J Invest Dermatol. 2019 May;139(5):1073-1081. (PMID: 30472058) J Cell Biochem. 2014 Jan;115(1):93-101. (PMID: 23904244) Nucleic Acids Res. 2005 Mar 01;33(4):1290-7. (PMID: 15741182) Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1117-27. (PMID: 19648252) Int J Womens Health. 2019 Apr 30;11:287-299. (PMID: 31118829) Oncogene. 2008 Apr 17;27(18):2575-82. (PMID: 17998940) Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51. (PMID: 12902539) Am J Physiol Cell Physiol. 2008 Feb;294(2):C460-6. (PMID: 18077608) Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7214-7221. (PMID: 30468464) Cancer Res. 2013 Jul 1;73(13):4098-111. (PMID: 23667173) J Am Coll Cardiol. 2002 Apr 17;39(8):1384-91. (PMID: 11955860) Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):457-464. (PMID: 30458987) Int J Biochem Cell Biol. 2011 Apr;43(4):632-41. (PMID: 21216304) FEBS Lett. 2013 Mar 1;587(5):488-95. (PMID: 23337879) J Bone Miner Res. 2011 Feb;26(2):229-38. (PMID: 21254230) World J Gastroenterol. 2003 Aug;9(8):1662-6. (PMID: 12918097) Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21179-84. (PMID: 19965369) Cell Signal. 2020 Jul;71:109548. (PMID: 31982550) Circ Res. 1989 Oct;65(4):1045-56. (PMID: 2551525) Genes Cancer. 2018 Jan;9(1-2):1-10. (PMID: 29725500) Int J Nanomedicine. 2017 Oct 13;12:7469-7482. (PMID: 29075114) Nature. 2005 Jun 9;435(7043):834-8. (PMID: 15944708) Sci Rep. 2017 Nov 24;7(1):16225. (PMID: 29176755) Circ Res. 2007 Feb 16;100(3):416-24. (PMID: 17234972) Oncol Lett. 2018 Nov;16(5):5679-5686. (PMID: 30344723) Biochem Biophys Res Commun. 2008 Apr 4;368(2):267-72. (PMID: 18230348) J Biol Chem. 2010 Aug 20;285(34):26599-607. (PMID: 20534588) Am J Transl Res. 2017 Jul 15;9(7):3184-3199. (PMID: 28804539) Asian Pac J Cancer Prev. 2012;13(1):255-60. (PMID: 22502680) J Invest Dermatol. 2009 Jul;129(7):1740-51. (PMID: 19212343) Prz Gastroenterol. 2019;14(1):26-38. (PMID: 30944675) Mol Cancer. 2015 Dec 15;14:208. (PMID: 26666173) Cytotechnology. 2019 Dec;71(6):1155-1165. (PMID: 31705333) Circ Res. 2000 Jun 23;86(12):1259-65. (PMID: 10864917) J Clin Invest. 2009 Dec;119(12):3666-77. (PMID: 19920351) Breast Cancer Res Treat. 2012 Aug;134(3):933-41. (PMID: 22350790) Dev Biol. 2007 Nov 15;311(2):359-68. (PMID: 17936265) Science. 1998 Jun 5;280(5369):1614-7. (PMID: 9616126) Cancer Res. 1994 Mar 15;54(6):1425-30. (PMID: 8137243) Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):748-754. (PMID: 27339596) Nat Genet. 2007 Feb;39(2):259-63. (PMID: 17220889) J Hepatol. 2012 Sep;57(3):584-91. (PMID: 22613005) Nat Commun. 2016 Mar 07;7:10872. (PMID: 26947250) Circ Res. 2014 Jan 31;114(3):565-71. (PMID: 24481846) J Hematol Oncol. 2010 Nov 24;3:46. (PMID: 21106054) Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15163-8. (PMID: 20699384) Circ Res. 2009 Dec 4;105(12):1164-76. (PMID: 19959782) Int J Mol Med. 2015 May;35(5):1395-402. (PMID: 25738546) Cardiovasc Res. 2007 Mar 1;73(4):689-98. (PMID: 17217936) Melanoma Res. 2008 Jun;18(3):184-90. (PMID: 18477892) Clin Cancer Res. 2008 May 1;14(9):2535-42. (PMID: 18451214) Eur J Pharm Sci. 2009 Nov 5;38(4):370-7. (PMID: 19733659) Bone. 2013 Aug;55(2):487-94. (PMID: 23579289) Biochem Biophys Res Commun. 2016 Sep 9;478(1):337-342. (PMID: 27422604) Genomics. 2005 Jun;85(6):782-9. (PMID: 15885504) Nat Genet. 2003 Nov;35(3):215-7. (PMID: 14528307) Cardiovasc Res. 2012 Mar 15;93(4):655-65. (PMID: 22227154) J Cell Physiol. 2015 Aug;230(8):1964-73. (PMID: 25656649) Sci Rep. 2017 Aug 14;7(1):8014. (PMID: 28808337) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Cardiovasc Res. 2007 Oct 1;76(1):81-90. (PMID: 17612514) Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13906-11. (PMID: 18784367) J Biol Chem. 2003 Sep 19;278(38):36027-31. (PMID: 12840017) Nature. 2008 Sep 4;455(7209):64-71. (PMID: 18668037) Nat Med. 2013 Jan;19(1):93-100. (PMID: 23223004) J Surg Res. 2014 Dec;192(2):317-25. (PMID: 25085702) Biomed Res Int. 2015;2015:864946. (PMID: 26509170) Mol Cancer Ther. 2009 May;8(5):1106-12. (PMID: 19435872) Br J Dermatol. 2020 Dec;183(6):1056-1064. (PMID: 32133614) Am J Physiol Cell Physiol. 2001 Jan;280(1):C53-60. (PMID: 11121376) Oncogene. 2010 Jun 17;29(24):3545-53. (PMID: 20400975) Hered Cancer Clin Pract. 2015 Feb 08;13(1):7. (PMID: 25705321) Cell Death Differ. 2021 May;28(5):1669-1687. (PMID: 33303976) J Invest Dermatol. 2015 Apr;135(4):960-969. (PMID: 25501033) Am J Pathol. 2007 Jun;170(6):1831-40. (PMID: 17525252) Am J Transl Res. 2017 Aug 15;9(8):3541-3557. (PMID: 28861147) Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2846-54. (PMID: 11087240) Med Sci Monit. 2012 Aug;18(8):BR309-314. (PMID: 22847192) Tumour Biol. 2013 Jun;34(3):1793-800. (PMID: 23479198) J Immunol. 2010 Jul 15;185(2):990-7. (PMID: 20548023) |
معلومات مُعتمدة: | FS/19/41/34478 United Kingdom BHF_ British Heart Foundation |
فهرسة مساهمة: | Keywords: bone; cancer; cardiovascular; cell differentiation; microRNAs |
المشرفين على المادة: | 0 (Cardiotonic Agents) 0 (MIRN214 microRNA, human) 0 (MicroRNAs) |
تواريخ الأحداث: | Date Created: 20211224 Date Completed: 20220120 Latest Revision: 20220520 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC8699121 |
DOI: | 10.3390/cells10123274 |
PMID: | 34943783 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!